This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Virpax Pharmaceuticals’s 8K filing here.
Virpax Pharmaceuticals Company Profile
Virpax Pharmaceuticals, Inc, a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain.
Featured Stories
- Five stocks we like better than Virpax Pharmaceuticals
- Utilities Stocks Explained – How and Why to Invest in Utilities
- Cerence Up 155% in 2 Days: SoundHound AI’s Fierce Competitor
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- Why Warren Buffett Is Selling: A Look at His Latest Market Moves
- Energy and Oil Stocks Explained
- Why Amazon Shares May Never Trade Below $200 Again
